Profile data is unavailable for this security.
About the company
Indivior PLC is a pharmaceutical company. The Company is engaged in developing medicines to treat substance use disorders (SUD), serious mental illnesses, and opioid overdose. It has a pipeline of product candidates designed to address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder, and co-morbidities, including schizophrenia. Its core products include SUBLOCADE (buprenorphine extended release) monthly injection; SUBOXONE Film (buprenorphine and naloxone sublingual film); SUBOXONE Tablet (buprenorphine and naloxone sublingual tablets), and SUBUTEX Tablet (buprenorphine sublingual tablets). Its products for the treatment of opioid disorders (OUD) are OPVEE (nalmefene) nasal spray for opioid overdose reversal, and PERSERIS (risperidone) extended-release injectable suspension for the treatment of schizophrenia in adults in the United States. Its portfolio of products is available in 37 countries.
- Revenue in GBP (TTM)874.51m
- Net income in GBP-107.50m
- Incorporated2014
- Employees1.05k
- LocationIndivior PLC10710 Midlothian TurnpikeSuite 125, North ChesterfieldCHESTERFIELD 23235United StatesUSA
- Phone+0 (804) 379-1090
- Websitehttps://www.indivior.com/en
Peer analysis
| Company | Revenue (TTM) | Net income (TTM) |
|---|---|---|
| FAES Farma SA | 398.36m | 81.37m |
| Jiangsu Kanion Pharmaceutical Co., Ltd. | 496.79m | 57.17m |
| Tarsus Pharmaceuticals Inc | 63.55m | -114.39m |
| Youcare Pharmaceutical Group Co Ltd | 428.59m | 10.46m |
| Indivior PLC | 874.51m | -107.50m |
| Harbin Pharmaceutical Group Co., Ltd. | 1.73bn | 60.38m |
| Collegium Pharmaceutical Inc | 439.54m | 76.14m |
| Sanofi Consumer Healthcare India Ltd | 72.63m | 20.93m |
| North China Pharmaceutical Co Ltd | 1.10bn | 5.47m |
| Nanjing Vazyme Biotech Co Ltd | 148.16m | 2.86m |
Institutional shareholders
| Holder | Shares | % Held |
|---|---|---|
| Two Seas Capital LPas of 20 Jun 2024 | 13.26m | 9.89% |
| Morgan Stanley & Co. International Plcas of 31 Dec 2023 | 9.74m | 7.27% |
| Oaktree Capital Management LPas of 09 Jul 2024 | 9.38m | 7.00% |
| Soci�t� G�n�rale Gestion SAas of 02 Jul 2024 | 6.77m | 5.05% |
| Scopia Capital Management LPas of 19 Mar 2024 | 6.29m | 4.69% |
| Fidelity Management & Research Co. LLCas of 30 Jun 2024 | 5.35m | 3.99% |
| Madison Avenue Partners LPas of 14 Nov 2023 | 4.63m | 3.45% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 4.52m | 3.37% |
| Goldman Sachs Internationalas of 31 Mar 2024 | 4.22m | 3.15% |
| BlackRock Investment Management (UK) Ltd.as of 08 Aug 2024 | 3.58m | 2.67% |
